The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Oct. 07, 2014
Filed:
Dec. 17, 2010
Nicolas Baurin, Arpagjon, FR;
Francis Blanche, Paris, FR;
Beatrice Cameron, Paris, FR;
Carsten Corvey, Frankfurt, DE;
Tarik Dabdoubi, Le Coudray Montceaux, FR;
Christian Engel, Frankfurt, DE;
Peter Florian, Frankfurt, DE;
Ingo Focken, Hochheim, DE;
Katja Kroll, Frankfurt, DE;
Jochen Kruip, Erzhausen, DE;
Christian Lange, Frankfurt, DE;
Thomas Langer, Frankfurt, DE;
Martin Lorenz, Frankfurt, DE;
Vincent Mikol, Charenton-le-Pont, FR;
Ercole Rao, Moerfelden-Waldorf, DE;
Peter Wonerow, Wildau, DE;
Nicolas Baurin, Arpagjon, FR;
Francis Blanche, Paris, FR;
Beatrice Cameron, Paris, FR;
Carsten Corvey, Frankfurt, DE;
Tarik Dabdoubi, Le Coudray Montceaux, FR;
Christian Engel, Frankfurt, DE;
Peter Florian, Frankfurt, DE;
Ingo Focken, Hochheim, DE;
Katja Kroll, Frankfurt, DE;
Jochen Kruip, Erzhausen, DE;
Christian Lange, Frankfurt, DE;
Thomas Langer, Frankfurt, DE;
Martin Lorenz, Frankfurt, DE;
Vincent Mikol, Charenton-le-Pont, FR;
Ercole Rao, Moerfelden-Waldorf, DE;
Peter Wonerow, Wildau, DE;
Sanofi, Paris, FR;
Abstract
The present invention discloses novel antibodies that specifically bind to the human platelet membrane protein Glycoprotein VI (GPVI) and their monovalent fragments or derivatives. The antibodies of the invention are antibodies from hybridoma clone 390 and fragment antibodies thereof able to induce a GPVI depletion phenotype. These antibodies and Fab fragments are able to block collagen binding and thus preventing platelet activation by collagen. The invention also relates to hybridoma clones and expression plasmids for the production of disclosed antibodies and Fab fragments. The present invention further refers to the uses of monovalent antibody fragments to manufacture research, diagnostic and immunotherapeutic agents for the treatment of thrombosis and other vascular diseases. The invention also concerns a Fab bearing a molecule at the C-terminal extremity, as well as method for prevention of recognition of Fab by antibodies using such modified Fab. The invention concerns a method for prevention of platelet activation when an anti-GP VI Fab is used.